SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Roots Analysis | PRODUCT CODE: 2112599

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 2112599

Bacteriophage Therapy Market by Target Indication, Route of Administration, Targeted Bacteria, and Geographical Regions - Trends and Forecast Till 2035

PUBLISHED:
PAGES: 221 Pages
DELIVERY TIME: 7-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4799
PDF & Excel & Summary Pack (Business Unit License)
USD 7999
PDF & Excel & Summary Pack (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

BACTERIOPHAGE THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global bacteriophage therapy market is estimated to grow from USD 66.5 million in the current year to USD 266.8 million by 2035, reflecting a compound annual growth rate (CAGR) of approximately 16.7% during the forecast period.

Bacteriophage Therapy Market - IMG1

Bacteriophage Therapy Market: Growth and Trends

The rapid rise of antimicrobial resistance (AMR) has accelerated the need for novel anti-infective strategies capable of addressing infections that no longer respond to conventional antibiotics. Notably, the World Health Organization estimates that AMR is directly associated with approximately 1.27 million deaths annually, a figure projected to rise sharply if left unaddressed. Escalating resistance rates, coupled with the limited availability of innovative antibacterial agents and growing concerns regarding microbiome disruption, have exposed significant gaps in existing treatment paradigms. As healthcare systems increasingly prioritize precision antimicrobial approaches, bacteriophage therapy has gained renewed attention as a promising alternative capable of addressing complex and drug-resistant bacterial infections.

Bacteriophage therapeutics employ naturally occurring viruses that selectively eliminate pathogenic bacteria while preserving beneficial microbial flora, offering a targeted mechanism of action that differs fundamentally from broad-spectrum antibiotics. Their ability to self-amplify at the infection site, disrupt bacterial biofilms and evolve alongside emerging bacterial resistance provides a distinct therapeutic advantage, particularly for persistent, recurrent and multidrug-resistant infections. These characteristics have positioned phage therapy as a complementary modality with the potential to reshape future infectious disease management.

The market has transitioned from an academically driven research field to a rapidly advancing clinical and commercial landscape, supported by increasing regulatory engagement, public-sector funding and strategic industry investment. Several biotechnology companies are advancing engineered phage platforms, pathogen-specific phage cocktails and combination therapies designed to improve efficacy, broaden bacterial coverage and minimize resistance development. As clinical evidence continues to strengthen and manufacturing technologies mature, bacteriophage therapeutics are expected to play an increasingly important role in the next generation of precision anti-infective therapies.

Growth Drivers: Factors Fueling Market Expansion

The growing prevalence of multidrug-resistant bacterial infections has exposed the limitations of conventional antibiotics, creating an urgent need for innovative antimicrobial modalities. The continued rise in AMR-related mortality, combined with increasing antibiotic treatment failures and the scarcity of novel antibacterial drugs, is accelerating interest in bacteriophage-based therapeutics. Their pathogen-specific mechanism of action, ability to preserve the native microbiome and potential to combat resistant bacterial strains position phage therapy as a promising solution for addressing the global AMR crisis.

Additionally, rapid progress in synthetic biology, genome engineering, bioinformatics and AI-enabled phage discovery is transforming the development of next-generation bacteriophage therapeutics. Advanced engineering platforms are enabling the design of optimized phage cocktails and genetically enhanced bacteriophages with broader bacterial coverage, improved therapeutic performance and reduced resistance potential. These innovations are shortening development timelines, improving manufacturing consistency and expanding opportunities for personalized anti-infective therapies, thereby strengthening investor confidence and accelerating market growth.

Market Challenges: Critical Barriers Hindering Progress

The absence of globally harmonised regulatory pathways for bacteriophage therapeutics remains a significant barrier to market growth. Existing approval frameworks are primarily tailored to conventional pharmaceuticals and often fail to accommodate the adaptive and highly specific nature of phage-based products. This regulatory uncertainty increases development risk, extends approval timelines and raises compliance requirements, particularly for customised and precision phage therapies.

Further, commercial-scale production of bacteriophage therapeutics requires highly controlled manufacturing processes to ensure product purity, potency and batch-to-batch consistency. The inherent biological variability of phages, coupled with the need for robust quality control and scalable purification technologies, increases production complexity and costs. These challenges are further amplified for personalised phage cocktails, where patient-specific formulations demand flexible manufacturing capabilities and rapid turnaround times.

Bacteriophage Therapy Market: Key Insights

The report delves into the current state of the bacteriophage therapy market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key insights include:

  • Strategic collaborations are accelerating bacteriophage therapeutic development. Companies are partnering with academic institutions, hospitals, and government organizations to expand phage libraries, validate clinical efficacy, and support regulatory submissions, thereby shortening development timelines and improving access to clinical samples for personalized phage therapy.
  • Government and non-dilutive funding continue to strengthen innovation in the market. Public agencies are actively supporting bacteriophage therapy programs to combat antimicrobial resistance (AMR).
  • BiomX has received approximately USD 40 million in non-dilutive funding from the US Defense Health Agency (DHA) and the Department of Navy through the Medical Technology Enterprise Consortium (MTEC) to advance its Staphylococcus aureus phage therapy programs.
  • Private investments are supporting late-stage clinical development of bacteriophage therapeutics. For instance, BiomX raised approximately USD 12 million to advance its BX004 Phase IIb program for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, reflecting sustained investor confidence in phage-based therapies.
  • Industry consolidation is strengthening bacteriophage technology capabilities. Strategic acquisitions, such as BiomX's acquisition of Adaptive Phage Therapeutics (APT), have expanded intellectual property, personalized phage therapy expertise, and phage bank resources, supporting long-term product development.
  • Clinical milestones are improving commercialization prospects for bacteriophage therapeutics. Companies are advancing from compassionate-use programs to controlled clinical trials, with BiomX initiating Phase IIb patient dosing for BX004, reflecting a maturing pipeline and stronger regulatory engagement.

Bacteriophage Therapy Market Segments

Roots Analysis segments the global bacteriophage therapy opportunity across the following parameters:

By Target Indication

  • Bacterial Dysentery
  • Enteric Infections
  • Gastrointestinal Infections
  • Multiple Infections
  • Prosthetic Joint Infection (PJI)
  • Urinary Tract Infections

By Route of Administration

  • Intravenous
  • Oral
  • Rectal
  • Topical

By Targeted Bacteria

  • Escherichia coli
  • Pseudomonas aeruginosa
  • Salmonella
  • Staphylococcus aureus
  • Streptococcus
  • Others

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Bacteriophage Therapy Market: Key Segments Insight

Urinary Tract Infections Segment Leads the Bacteriophage Therapy Market

Based on our market assessment, the urinary tract infections segment holds the highest share of the bacteriophage therapy market. This leadership is driven by the high global prevalence of recurrent and multidrug-resistant UTIs, particularly those caused by Escherichia coli, coupled with growing clinical evidence supporting phage therapy as an adjunct or alternative to antibiotics.

On the other hand, the prosthetic joint infection (PJI) segment is projected to witness the highest CAGR during the forecast period. This accelerated growth is attributed to the increasing volume of orthopedic implant procedures worldwide and the unique ability of bacteriophages to penetrate and disrupt bacterial biofilms that are difficult to eradicate using conventional antibiotics.

Oral Route Captures the Largest Share and Topical Segment to Register Fastest Growth

Based on route of administration, the oral segment currently captures the majority of the bacteriophage therapy market. This dominance is supported by advances in enteric-coated and microencapsulated phage formulations that improve phage survival through the gastric environment.

Meanwhile, the topical segment is likely to grow at a relatively higher CAGR, fueled by the rising prevalence of chronic wound infections, diabetic foot ulcers, and surgical site infections.

North America Maintains Market Leadership and Asia-Pacific Emerges as the Fastest-Growing Region

According to our market projections, North America is expected to retain the highest share of global market revenue through the forecast period. This highest share is driven by an advanced clinical development ecosystem, strong funding environment, and the presence of specialized phage therapy companies including Locus Biosciences, Adaptive Phage Therapeutics, and Armata Pharmaceuticals.

Meanwhile, Asia-Pacific is projected to grow at a higher CAGR through 2035. This highest growth is driven by rising AMR burden, expanding biotechnology capabilities, and growing government focus on infectious disease management across China, India, Japan, South Korea, and Australia.

Example Players in Bacteriophage Therapy Market

  • Adaptive Phage Therapeutics
  • ContraFect
  • Eliava BioPreparations
  • Micreos
  • NPO Microgen
  • Phagelux AgriHealth
  • Pherecydes Pharma

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Small Company, France
  • Senior Director, Head of Data-Science, Small Company, Israel
  • Project Leader, Very Large Company, France
  • Independent Consultant
  • Founder and Chief Executive Officer, Small Company, Greece
  • Co-Founder and Chief Executive Officer, Small Company, Switzerland
  • Chief Financial Officer, Mid-sized Company, US
  • Chief Scientific Officer, Small Company, US
  • Co-Founder, Small Company, US
  • Staff Scientist & Principal Investigator, Very Large Company, US
  • Production Specialist, Small Company, Portugal
  • Professor of Medicine, Very Large Company, US
  • Independent Researcher

BACTERIOPHAGE THERAPY MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bacteriophage therapy market, focusing on key market segments, including target indication, route of administration, targeted bacteria, and geographical regions.
  • Bacteriophage Therapy: Market Landscape: Historical evolution and biology of bacteriophages, applications, advantages, and limitations of bacteriophage therapy, along with an assessment of the drug pipeline by phase of development, therapeutic area, targeted bacterial strain, target disease indication, type of therapy, and route of administration.
  • Developer Landscape: A detailed assessment of the developer landscape, based on parameters such as year of establishment, company size, and location of headquarters.
  • Company and Drug Profiles: In-depth profiles of prominent players engaged in offering bacteriophage therapeutics, featuring information on company overview, financials, pipeline, and recent developments.
  • Clinical Trial Analysis: An analysis of registered clinical trials by registration year, enrolled patient population, trial status, trial phase, study design, type of sponsor / collaborator, and geography.
  • Patent Analysis: An analysis of patents filed / granted related to bacteriophage therapy, based on parameters such as publication year, application year, jurisdiction, CPC symbols, type of applicant, patent benchmarking, and patent valuation.
  • Publication Benchmarking Analysis: An analysis of scientific publications by year, article type, popular keywords, publishers, journals, and journal impact factor.
  • Academic Grants Analysis: An analysis of academic grants awarded, based on parameters such as year of award, amount awarded, administering institute, support period, and recipient organization.
  • Funding and Investments Analysis: A detailed analysis of funding instances and amounts raised, by year, type of funding, investor, and geography.
  • Partnerships and Collaborations: A detailed analysis of partnerships and collaborations, by year, type of partnership, therapeutic area, application area, and geography.
  • Start-up Health Indexing: A proprietary benchmarking framework for start-up developers, based on pipeline strength, pipeline maturity, indication diversity, patent count, funding amount, and partnership activity.
  • Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth, including a Penetration-Growth (P-G) Matrix across geographies.
  • Executive Insights: Verbatim transcripts of interviews held with CEOs, senior scientists, and independent researchers active in the bacteriophage therapy domain.

Key Questions Answered in this Report

  • Which are the leading companies in the bacteriophage therapy market?
  • Which target indication and targeted bacteria segment dominate the bacteriophage therapy market?
  • Which region dominates the bacteriophage therapy market, and which region is growing the fastest?
  • What are the key trends observed in the bacteriophage therapy market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by bacteriophage therapy developers?
  • What is the current and future market size, and what is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • Which companies are the most active in terms of clinical trials, patents, funding, and partnerships?

Reasons to Buy this Report

This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the Bacteriophage Therapy market.

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments, valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges, empowering data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector, and in understanding whether those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience, in order to tailor products or services effectively.
  • The report equips new entrants with the requisite information regarding this market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary Insights Pack
  • Complementary PPT Insights Pack
  • Complementary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older
Show more
Product Code: RA100388

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Historical Evolution of Bacteriophages
  • 6.3. Biology of Bacteriophages
  • 6.4. Introduction to Bacteriophage Therapy
  • 6.5. Applications of Bacteriophage Therapy
  • 6.6. Advantages of Bacteriophage Therapy
  • 6.7. Limitations of Bacteriophage Therapy
  • 6.8. Conclusion

7. BACTERIOPHAGE THERAPY: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Bacteriophage Therapy: Drug Pipeline
    • 7.2.1. Analysis by Phase of Development
    • 7.2.2. Analysis by Therapeutic Area
    • 7.2.3. Analysis by Phase of Development and Therapeutic Area
    • 7.2.4. Analysis by Targeted Bacterial Strain
    • 7.2.5. Analysis by Target Disease Indication
    • 7.2.6. Analysis by Type of Therapy
    • 7.2.7. Analysis by Route of Administration
  • 7.3. Information on Bacteriophage Related Technologies

8. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Bacteriophage Therapeutics: List of Developers
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters
    • 8.2.4. Analysis by Company Size and Location of Headquarters
    • 8.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics

9. COMPANY AND DRUG PROFILES

  • 9.1. Chapter Overview
  • 9.2. Adaptive Phage Therapeutics*
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Pipeline Overview
    • 9.2.4. Recent Developments and Future Outlook
  • Similar details are presented for other companies mentioned below (based on information in the public domain)
  • 9.3. ContraFect
  • 9.4. Eliava BioPreparations
  • 9.5. Micreos
  • 9.6. NPO Microgen
  • 9.7. Phagelux
  • 9.8. Pherecydes Pharma

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Bacteriophage Therapy Market: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 10.3.3. Analysis by Trial Status
    • 10.3.4. Analysis by Trial Phase and Enrolled Patient Population
    • 10.3.5. Analysis by Study Design
    • 10.3.6. Analysis by Type of Sponsor / Collaborator
    • 10.3.7. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.8. Regional Analysis
      • 10.3.8.1. Analysis by Number of Registered Trials
      • 10.3.8.2. Analysis by Enrolled Patient Population

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Bacteriophage Therapy: Patent Analysis
    • 11.3.1. Analysis by Publication Year
    • 11.3.2. Analysis by Patent Application Year
    • 11.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
    • 11.3.4. Analysis by Geography
    • 11.3.5. Analysis by CPC Symbols
    • 11.3.6. Analysis by Type of Applicant
    • 11.3.7. Leading Players: Analysis by Number of Patents
  • 11.4. Bacteriophage Therapy: Patent Benchmarking
    • 11.4.1. Analysis by Patent Characteristics
  • 11.5. Bacteriophage Therapy: Patent Valuation
  • 11.6. List of Leading Patents

12. PUBLICATION BENCHMARKING ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
    • 12.2.1. Analysis by Year of Publication
    • 12.2.2. Analysis by Type of Article
    • 12.2.3. Analysis by Popular Keywords
    • 12.2.4. Popular Publishers: Analysis by Number of Publications
    • 12.2.5. Popular Journals: Analysis by Number of Publications
    • 12.2.6. Popular Journals: Analysis by Journal Impact Factor
    • 12.2.7. Publications: Timeline Analysis
  • 12.3. Publication Benchmarking

13. ACADEMIC GRANTS ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Bacteriophage Therapy: Academic Grant Analysis
    • 13.3.1. Analysis by Year of Grant Award
    • 13.3.2. Analysis by Amount Awarded
    • 13.3.3. Analysis by Administering Institute Center
    • 13.3.4. Analysis by Support Period
    • 13.3.5. Analysis by Funding Institute Center and Support Period
    • 13.3.6. Analysis by Type of Grant Application
    • 13.3.7. Analysis by Purpose of Grant Award
    • 13.3.8. Analysis by Activity Code
    • 13.3.9. Word Cloud Analysis: Emerging Focus Areas
    • 13.3.10. Analysis by Study Section Involved
    • 13.3.11. Popular NIH Departments: Analysis by Number of Grants
    • 13.3.12. Analysis by Type of Recipient Organization
    • 13.3.13. Prominent Program Officers: Analysis by Number of Grants
    • 13.3.14. Popular Recipient Organizations: Analysis by Number of Grants
    • 13.3.15. Regional Distribution of Recipient Organizations

14. FUNDING AND INVESTMENTS ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. Bacteriophage Therapy Market: List of Funding and Investments
    • 14.3.1. Analysis by Year of Investment
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
    • 14.3.5. Investors Analysis
    • 14.3.6. Regional Distribution by Amount Invested
  • 14.4. Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
    • 15.3.3. Analysis by Year of Partnership and Type of Partner
    • 15.3.4. Analysis by Therapeutic Area
    • 15.3.5. Analysis by Application Area
    • 15.3.6. Most Active Players: Analysis by Number of Partnerships
    • 15.3.7. Regional Analysis
      • 15.3.7.1. Intercontinental and Intracontinental Agreements

16. START-UP HEALTH INDEXING

  • 16.1. Chapter Overview
  • 16.2. Bacteriophage Therapeutics Developers: Start-ups
    • 16.2.1. Analysis by Location of Headquarters
  • 16.3. Benchmarking of Start-ups
    • 16.3.1. Analysis by Pipeline Strength
    • 16.3.2. Analysis by Pipeline Maturity
    • 16.3.3. Analysis by Indication Diversity
    • 16.3.4. Analysis by Number of Patents
    • 16.3.5. Analysis by Funding Amount
    • 16.3.6. Analysis by Partnership Activity
    • 16.3.7. Start-ups Health Indexing: Roots Analysis Perspective

17. GLOBAL BACTERIOPHAGE THERAPY MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 17.4. Roots Analysis Perspective on Market Growth
  • 17.5. Scenario Analysis
    • 17.5.1. Conservative Scenario
    • 17.5.2. Optimistic Scenario
  • 17.6. Key Market Segmentations

18. BACTERIOPHAGE THERAPY MARKET, BY TARGET INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Bacteriophage Therapy Market: Distribution by Target Indication
    • 18.3.1. Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.2. Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.3. Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.4. Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.5. Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.6. Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 18.4. Data Triangulation and Validation

19. BACTERIOPHAGE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Bacteriophage Therapy Market: Distribution by Route of Administration
    • 19.3.1. Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.2. Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.3. Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.4. Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 19.4. Data Triangulation and Validation

20. BACTERIOPHAGE THERAPY MARKET, BY TARGETED BACTERIA

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Bacteriophage Therapy Market: Distribution by Targeted Bacteria
    • 20.3.1. Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.2. Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.3. Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.4. Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.5. Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.6. Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 20.4. Data Triangulation and Validation

21. BACTERIOPHAGE THERAPY MARKET, BY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Bacteriophage Therapy Market: Distribution by Geographical Regions
    • 21.3.1. Bacteriophage Therapy Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.2. Bacteriophage Therapy Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.3. Bacteriophage Therapy Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.4. Bacteriophage Therapy Market in Rest of the World: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 21.4. Market Dynamics Assessment
    • 21.4.1. Penetration-Growth (P-G) Matrix
  • 21.5. Data Triangulation and Validation

22. CONCLUSION

23. EXECUTIVE INSIGHTS

24. APPENDIX I: TABULATED DATA

25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Show more
Product Code: RA100388

List of Tables

  • Table 7.1 Bacteriophage Therapeutics: Information on Developer, Phase of Development, Bacterial Target, Target Disease Indication, Therapeutic Area
  • Table 7.2 Bacteriophage Therapeutics: Information on Type of Therapy and Route of Administration
  • Table 7.3 Bacteriophage Therapeutics: Information on Bacteriophage Related Technologies
  • Table 8.1 Bacteriophage Therapeutics: List of Developers
  • Table 9.1 Eliava BioPreparations: Company Overview
  • Table 9.2 Eliava BioPreparations: Pipeline Overview
  • Table 9.3 Micreos: Company Overview
  • Table 9.4 Micreos: Pipeline Overview
  • Table 9.5 NPO Microgen: Company Overview
  • Table 9.6 NPO Microgen: Pipeline Overview
  • Table 9.7 ContraFect: Company Overview
  • Table 9.8 ContraFect: Pipeline Overview
  • Table 9.9 Adaptive Phage Therapeutics: Company Overview
  • Table 9.10 Adaptive Phage Therapeutics: Pipeline Overview
  • Table 9.11 Phagelux: Company Overview
  • Table 9.12 Phagelux: Pipeline Overview
  • Table 9.13 Pherecydes Pharma: Company Overview
  • Table 9.14 Pherecydes Pharma: Pipeline Overview
  • Table 11.1 List of Top CPC Sections
  • Table 11.2 List of Top CPC Symbols
  • Table 11.3 List of Top CPC Codes
  • Table 11.4 Patent Analysis: Summary of Benchmarking
  • Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 12.1 Publication Benchmarking: List of Top 50 Publications
  • Table 14.1 Bacteriophage Therapy: List of Funding and Investments, Since 2017
  • Table 14.2 Funding and Investment Analysis: Summary of Investment
  • Table 15.1 Bacteriophage Therapy: List of Partnerships and Collaborations, Since 2017
  • Table 24.1 Bacteriophage Therapy: Distribution by Phase of Development
  • Table 24.2 Bacteriophage Therapy: Distribution by Therapeutic Area
  • Table 24.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
  • Table 24.4 Bacteriophage Therapy: Distribution by Targeted Bacterial Strain
  • Table 24.5 Bacteriophage Therapy: Distribution by Target Disease Indication
  • Table 24.6 Bacteriophage Therapy: Distribution by Type of Therapy
  • Table 24.7 Bacteriophage Therapy: Distribution by Route of Administration
  • Table 24.8 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Table 24.9 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Table 24.10 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Table 24.11 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Table 24.12 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Table 24.13 Clinical Trial Analysis: Scope and Methodology
  • Table 24.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
  • Table 24.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
  • Table 24.16 Clinical Trial Analysis: Distribution by Trial Status
  • Table 24.17 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Table 24.18 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Table 24.19 Clinical Trial Analysis: Distribution by Study Design
  • Table 24.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 24.21 Most Active Players: Distribution by Number of Registered Trials
  • Table 24.22 Geographical Analysis: Distribution by Number of Registered Trials
  • Table 24.23 Geographical Analysis: Distribution by Enrolled Patient Population
  • Table 24.24 Patent Analysis: Distribution by Type of Patent
  • Table 24.25 Patent Analysis: Cumulative Distribution by Publication Year
  • Table 24.26 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Table 24.27 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
  • Table 24.28 Patent Analysis: Distribution by Geography
  • Table 24.29 Patent Analysis: Distribution by CPC Symbols
  • Table 24.30 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 24.31 Leading Industry Players: Distribution by Number of Patents
  • Table 24.32 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 24.33 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Table 24.34 Patent Analysis: Distribution by Patent Age
  • Table 24.35 Patent Valuation Analysis
  • Table 24.36 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
  • Table 24.37 Publication Benchmarking Analysis: Distribution by Type of Article
  • Table 24.38 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Table 24.39 Popular Publishers: Distribution by Number of Publications
  • Table 24.40 Popular Journals: Distribution by Number of Publications
  • Table 24.41 Popular Journals: Distribution by Journal Impact Factor
  • Table 24.42 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
  • Table 24.43 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
  • Table 24.44 Grant Analysis: Distribution by Administering Institute Center
  • Table 24.45 Grant Analysis: Distribution by Support Period
  • Table 24.46 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 24.47 Grant Analysis: Distribution by Type of Grant Application
  • Table 24.48 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 24.49 Grant Analysis: Distribution by Activity Code
  • Table 24.50 Grant Analysis: Distribution by Study Section Involved
  • Table 24.51 Popular NIH Departments: Distribution by Number of Grants
  • Table 24.52 Grant Analysis: Distribution by Types of Recipient Organization
  • Table 24.53 Most Prominent Program Officers: Distribution by Number of Grants
  • Table 24.54 Popular Recipient Organization: Distribution by Number of Grants
  • Table 24.55 Grant Analysis: Regional Distribution of Recipient Organization
  • Table 24.56 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
  • Table 24.57 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
  • Table 24.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
  • Table 24.59 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
  • Table 24.60 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Table 24.61 Most Active Investors: Distribution by Number of Instances
  • Table 24.62 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
  • Table 24.63 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
  • Table 24.64 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 24.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
  • Table 24.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
  • Table 24.67 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 24.68 Partnerships and Collaborations: Distribution by Application Area
  • Table 24.69 Most Active Players: Distribution by Number of Partnerships
  • Table 24.70 Partnerships and Collaborations: Regional Distribution
  • Table 24.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 24.72 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 24.73 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 24.74 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 24.75 Startup-Health Indexing: Distribution by Indication Diversity
  • Table 24.76 Startup-Health Indexing: Distribution by Number of Patents
  • Table 24.77 Startup-Health Indexing: Distribution by Funding Amount
  • Table 24.78 Start-up Health Indexing: Roots Analysis Perspective
  • Table 24.79 Start-up Health Indexing: Leading Companies
  • Table 24.80 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 24.81 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
  • Table 24.82 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
  • Table 24.83 Global Bacteriophage Therapy Market: Distribution by Target Indication
  • Table 24.84 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.85 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.86 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.87 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.88 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.89 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.90 Global Bacteriophage Therapy Market: Distribution by Route of Administration
  • Table 24.91 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.92 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.93 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.94 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.95 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
  • Table 24.96 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.97 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.98 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.99 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.100 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.101 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.102 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
  • Table 24.103 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.104 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.105 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.106 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 6.1 History Timeline of Bacteriophage
  • Figure 6.2 Bacteriophage Replication Cycle
  • Figure 6.3 Advantages of Bacteriophage Therapy
  • Figure 6.4 Limitations of Bacteriophage Therapy
  • Figure 7.1 Bacteriophage Therapy: Distribution by Phase of Development
  • Figure 7.2 Bacteriophage Therapy: Distribution by Therapeutic Area
  • Figure 7.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
  • Figure 7.4 Bacteriophage Therapeutics: Distribution by Targeted Bacterial Strain
  • Figure 7.5 Bacteriophage Therapeutics: Distribution by Target Disease Indication
  • Figure 7.6 Bacteriophage Therapeutics: Distribution by Type of Therapy
  • Figure 7.7 Bacteriophage Therapeutics: Distribution by Route of Administration
  • Figure 8.1 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Figure 8.2 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Figure 8.3 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 8.4 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Figure 8.5 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Figure 10.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Figure 10.6 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.10 Geographical Analysis: Distribution by Number of Registered Trials
  • Figure 10.11 Geographical Analysis: Distribution by Enrolled Patient Population
  • Figure 11.1 Patent Analysis: Distribution by Type of Patent
  • Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year
  • Figure 11.3 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Figure 11.4 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
  • Figure 11.5 Patent Analysis: Distribution by Geography
  • Figure 11.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 11.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 11.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 11.11 Patent Analysis: Distribution by Patent Age
  • Figure 11.12 Patent Valuation Analysis
  • Figure 12.1 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
  • Figure 12.2 Publication Benchmarking Analysis: Distribution by Type of Article
  • Figure 12.3 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Figure 12.4 Popular Publishers: Distribution by Number of Publications
  • Figure 12.5 Popular Journals: Distribution by Number of Publications
  • Figure 12.6 Popular Journals: Distribution by Journal Impact Factor
  • Figure 12.7 Timeline Analysis: Distribution by Article Type and Average Time to Publish
  • Figure 12.8 Timeline Analysis: Distribution by Journal Impact Factor and Average Time to Publish
  • Figure 12.9 Timeline Analysis: Distribution by Type of Article and Maximum Time to Publish
  • Figure 12.10 Timeline Analysis: Distribution by Journal Impact Factor and Maximum Time to Publish
  • Figure 12.11 Publication Benchmarking
  • Figure 13.1 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
  • Figure 13.2 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
  • Figure 13.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 13.4 Grant Analysis: Distribution by Support Period
  • Figure 13.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 13.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 13.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 13.8 Grant Analysis: Distribution by Activity Code
  • Figure 13.9 Word Cloud: Emerging Focus Areas
  • Figure 13.10 Grant Analysis: Distribution by Study Section Involved
  • Figure 13.11 Popular NIH Departments: Distribution by Number of Grants
  • Figure 13.12 Grant Analysis: Distribution by Types of Recipient Organization
  • Figure 13.13 Most Prominent Program Officers: Distribution by Number of Grants
  • Figure 13.14 Popular Recipient Organization: Distribution by Number of Grants
  • Figure 13.15 Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
  • Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
  • Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
  • Figure 14.4 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
  • Figure 14.5 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Figure 14.6 Most Active Investors: Distribution by Number of Instances
  • Figure 14.7 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
  • Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
  • Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
  • Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
  • Figure 15.5 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 15.6 Partnerships and Collaborations: Distribution by Application Area
  • Figure 15.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 15.8 Partnerships and Collaborations: Regional Distribution
  • Figure 15.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 16.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 16.2 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 16.3 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 16.4 Startup-Health Indexing: Distribution by Indication Diversity
  • Figure 16.5 Startup-Health Indexing: Distribution by Number of Patents
  • Figure 16.6 Startup-Health Indexing: Distribution by Funding Amount
  • Figure 16.7 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 16.8 Start-up Health Indexing: Leading Companies
  • Figure 17.1 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 17.2 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
  • Figure 17.3 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
  • Figure 17.4 Global Bacteriophage Therapy Market: Distribution by Target Indication
  • Figure 18.1 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.2 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million) Figure 18.3 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.4 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.5 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.6 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.1 Global Bacteriophage Therapy Market: Distribution by Route of Administration
  • Figure 19.2 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.3 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.4 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.5 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.1 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
  • Figure 20.2 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.3 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.4 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.5 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.6 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.7 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.1 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
  • Figure 21.2 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.3 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.4 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.5 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 22.1 Concluding Remarks: Market Landscape
  • Figure 22.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 22.3 Concluding Remarks: Patent Analysis
  • Figure 22.4 Concluding Remarks: Publication Benchmarking Analysis
  • Figure 22.5 Concluding Remarks: Academic Grants Analysis
  • Figure 22.6 Concluding Remarks: Funding and Investment Analysis
  • Figure 22.7 Concluding Remarks: Partnerships and Collaborations
  • Figure 22.8 Concluding Remarks: Start-up Health Indexing
  • Figure 22.9 Concluding Remarks: Market Sizing and Opportunity Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!